Multi-dose disposable pen with tirzepatide 40 mg / 3 ml (dual GLP-1 / GIP incretin agonist)
In stock — dispatch within 48h
❄️ Temperature-controlled delivery (2–8°C) across the EU.
AFIRA Tirzepatide 40 mg / 3 ml is a pre-filled multi-dose pen containing 40 mg of high-purity tirzepatide in 3 ml sterile liquid (13.33 mg/ml). Tailored specifically for initiation and early titration regimens (2.5 mg and 5.0 mg weekly schedules), it provides multi-week continuous coverage in a single sleek pen device.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By simultaneously activating both incretin pathways, it exerts synergistic metabolic control: promoting glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric motility, and stimulating central hypothalamic satiety circuits to curb appetite and enhance peripheral insulin sensitivity.
Multi-dose applicator with click dial selector. Affix a new sterile needle prior to injection and administer subcutaneously at 90° into abdominal or thigh adipose tissue.
To ensure gastrointestinal tolerability, Tirzepatide administration must follow a stepwise escalation protocol. Treatment initiates at a low starting dose of 2.5 mg subcutaneously once weekly for the initial 4 weeks (adaptation phase). The dose is then increased to 5.0 mg once weekly. Subsequent increments of 2.5 mg may occur at minimum 4-week intervals based on clinical assessment and tolerance, up to the maximum dose of 15.0 mg weekly.
| Active substance | Tirzepatide (CAS 2023706-61-5) |
|---|---|
| Total dose | 40 mg |
| Cartridge volume | 3.0 mL (13.33 mg/mL) |
| Device type | Pre-filled multi-dose pen |
| Route of administration | Subcutaneous (SC) 90° |
| Manufacturer / Brand | Afira Biosystems |
| Storage | 2°C – 8°C (Do not freeze) |
Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from direct light. Do not freeze. For pre-filled pens: once in use, the pen may be kept at room temperature (below 30°C / 86°F) for up to 21-28 days. For reconstituted vials: maintain in refrigerator at 2°C to 8°C and use sterile single-use syringes.
The 40 mg pen is ideal for patients starting therapy through the 2.5 mg and 5.0 mg weekly titration phases, providing up to 8-10 weeks of treatment.
